Abstract

To date, Coronavirus disease (COVID-19) has caused high morbidity and mortality worldwide. To counteract the pandemic scenario, several vaccines against the etiological factor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed and tested. At the end of December 2020, BNT162b2 (Comirnaty, Pfizer-BioNTech) was the first and only authorized vaccine in Italy for selected categories, such as healthcare workers, fragile patients and people aged over 80 years old. To master our knowledge about BNT162b2 adverse reactions (ARs), an active surveillance system based on instant messaging was realized for voluntary participants who had been vaccinated at COVID-19 Vaccination Center of the Palermo University Hospital. Overall, 293 vaccinated persons were included in this study, which were more frequently healthcare workers (n = 207, 70.6% with a median age of 36 years, IQR = 29–55) followed by health professional students (n = 31, 10.6% with a median age of 27 years, IQR = 25–29), reporting 82.6% of at least one local or systemic AR. In details, the frequency of at least one local or systemic AR after the second dose of Comirnaty (n = 235, 80.2%) was statistically significant with higher value in comparison to the first one (n = 149, 50.9%; p < 0.001). However, local pain, swelling, joint pain and muscular pain after the second dose were the symptom causing a statistically significant working limitation. The youngest persons showed a higher risk to have either local or systemic ARs (aOR = 7.5, CI 95% = 2.9–18.9), while females had a higher risk of having systemic ARs (aOR = 1.8, CI 95% = 1.1–3.0). Despite the small sample examined, this active surveillance system by instant messaging seems to detect a higher ARs prevalence with respect to data obtained by the passive surveillance. Further studies could be required in order to optimize this clinical monitoring that could be considered an efficient and timely active surveillance.

Highlights

  • The aim of this study is to evaluate the use of an active adverse reactions (ARs) surveillance based on instant text messages as a method for a timely identifying of ARs, including those with a mild presentation

  • After removing 102 respondents (25.8%) without matching diaries for the first and the second dose, 293 persons were included in the analysis (Figure 1)

  • This study evaluated the feasibility of an active surveillance system by instant phone text messaging to early detect local and systemic ARs after BNT162b2 vaccination

Read more

Summary

Introduction

Coronavirus disease 2019 (COVID-19) is a life-threatening condition [1,2] caused by severe acute respiratory coronavirus 2 syndrome (SARS-CoV-2) [1], being worldwide lethal in ~2% of cases [2]. To reduce its morbidity and mortality, the most efficacious prevention strategy is vaccination [2]. Healthcare workers are one of the principal targets of vaccination because of their occupational exposure [2,3]. At least 300 vaccines against SARS-CoV-2 are being experimented [4]. The first available to be administered in Italy was BNT162b2 (Comirnaty, PfizerBioNTech) [2], whose main constituent is the mRNA encoding the SARS-CoV-2 spike

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call